Page 280«..1020..279280281282..290300..»

Category Archives: Transhuman News

Psoriatic Arthritis and Dizzy Spells: The Connection, Treatment – Healthline

Posted: June 24, 2022 at 9:37 pm

Psoriatic arthritis is a type of arthritis that affects about 20 to 30 percent of people with the autoimmune condition psoriasis. It develops when your immune system attacks healthy cells in your joints, leading to symptoms like joint pain, stiffness, or swelling.

For some people, symptoms can be severe enough to cause permanent disability.

Psoriasis and psoriatic arthritis can have many complications caused by inflammation throughout your body. Inflammation in your inner ear can cause dizziness or vertigo. Some medications used to treat psoriasis can also lead to these side effects.

Read on to learn more about the connection between psoriatic arthritis, dizziness, and vertigo.

Psoriasis and psoriatic arthritis raise levels of pro-inflammatory molecules called cytokines throughout your body. Elevated levels of these molecules lead to chronic inflammation that can raise your risk of many seemingly unrelated conditions, like:

Vertigo and dizziness are also potential complications of psoriatic arthritis. They develop mainly because of an atypical immune response directed against cells in your inner ear.

When your immune system attacks these cells, it can lead to inflammation and dysfunction of your vestibular system. Your vestibular system is a series of bony labyrinths in your inner ear that helps regulate your sense of balance.

In a small 2017 study, researchers found evidence that people with psoriatic arthritis had a higher frequency of vestibular dysfunction than the general population.

Among 60 people with psoriatic arthritis and 60 controls, one-third of people with psoriatic arthritis had vestibular dysfunction compared with only 6 percent of people in the control group.

Psoriasis is often treated with drugs like TNF-alphas inhibitors, T-lymphocyte inhibitors, and interleukin inhibitors. Some of the medications used to treat psoriasis, like the following, can potentially cause dizziness as a side effect:

Vertigo is often confused with dizziness. The two conditions are similar but not the same.

Vertigo is the feeling the world is spinning in the absence of movement. Dizziness is a more general term that refers to the feeling that you or your surroundings are moving when theyre not.

Inflammation in your inner ear associated with psoriatic arthritis can also potentially contribute to the development of vertigo.

In the 2017 study, researchers found that two people with psoriatic arthritis had vertigo, versus no one in the control group.

Treating psoriatic arthritis may help reduce associated inflammation and help ease dizziness or vertigo. Treatment for psoriatic arthritis focuses on:

The main medications for psoriatic arthritis include:

Vestibular rehabilitation is an exercise program that may help reduce dizziness or vertigo. Research has found that it can be effective for treating symptoms of many inner ear disorders. Its usually performed by a physical or occupational therapist with specialized training.

Psoriatic arthritis primarily affects the joints in your fingers, wrists, ankles, or knees. Symptoms can include:

Some people also experience symptoms that affect their nails. They can include:

If psoriatic arthritis isnt treated properly, you can develop other health problems like:

Its generally a good idea to visit a doctor any time you have dizziness or vertigo without a known cause.

Its important to seek immediate emergency medical attention if you also have symptoms that can indicate a medical emergency, like:

Most people who develop psoriatic arthritis already have a diagnosis of psoriasis. Regular follow-ups with your doctor are an important part of treating psoriasis. Its a good idea to visit your doctor if:

Dizziness and vertigo are potential side effects of psoriatic arthritis.

They can develop due to inflammation in the part of your inner ear that controls your balance called your vestibular system. Some medications used to treat psoriatic arthritis can also potentially cause these symptoms.

If you have psoriasis or psoriatic arthritis, its important to visit a doctor any time you notice new symptoms. A doctor can help you rule out other causes of these new symptoms and help you develop the best treatment plan.

Follow this link:
Psoriatic Arthritis and Dizzy Spells: The Connection, Treatment - Healthline

Posted in Psoriasis | Comments Off on Psoriatic Arthritis and Dizzy Spells: The Connection, Treatment – Healthline

Could 2023 Be a Breakout Year for This Pharma Stock? – The Motley Fool

Posted: at 9:37 pm

A Food and Drug Administration (FDA) approval for a highly anticipated treatment is the kind of news that can make a company's stock skyrocket, even during a bear market -- like the one we're in now.

One company hoping for such success is Arcutis Biotherapeutics (ARQT -6.91%). It has been developing a treatment for Seborrheic dermatitis -- a skin disorder that causes scaly skin, or dandruff-like flakes, on the face and scalp. It affects 7% of the global population. There are treatments on the market, but none has been developed that can clear it up for good. So companies that develop a successful way to fight the disease have a promising opportunity.

Arcutis is awaiting the outcome of an FDA review that would expand its customer base and boost revenue. Should investors be as equally excited? Let's take a closer look.

In September, I provided readers with an article discussing a pending FDA approval for a therapy from Arcutis that treats psoriasis. The company is now using a similarly based approach to treating dermatitis. That, together with $225 million in newly secured debt financing, could help 2023 be a huge year for the company.

After the FDA accepted its application in December, Arcutis received a path to that needed financing by way of SLR Capital Partners, which is providing $75 million upon closing of the loan facility with the potential for another $125 million upon FDA approval of its current drug, roflumilast. The final $25 million would be achievable as Arcutis hits certain revenue milestones.

With top treatments like Otezla already on the market from big names like Amgen, Arcutis could benefit from offering a deeper pipeline that reaches more potential customers. And so the company is also developing a foam version of roflumilast -- which should please investors.

With the funding in place, Arcutis is closing in on the July 29 PDUFA date, which is when the company can expect the FDA's response to its submission. Arcutis hopes it will bring FDA approval to its roflumilast cream to treat plaque psoriasis -- a projected $47 billion market by 2029, growing at a compound annual rate of 9%.

The cream form of roflumilast to treat psoriasis could be worth $1 billion in annual revenue. In trials, it achieved favorable efficacy against Otezla. Based on its non-steroidal form, it's expected to be offered at a lower price than the oral Otezla, and could likely come with less side effects such as nausea, headaches, and diarrhea reported by 20% of Otezla patients.

Now, Arcutis is furthering its development of roflumilast to incorporate a foam form of the treatment in order to serve those who suffer from seborrheic dermatitis, which impacts the face and scalp. In phase 3 clinical trials, the treatment achieved an 80% success rate compared to 59% in the control group receiving a placebo treatment, with improvement showing as early as the second week of treatment. The company also achieved success when it comes to variables related to itching, scaling, and redness -- 66% success versus 42% of those on a placebo.

Based on feedback from the FDA, Arcutis has high hopes for eventual approval, with no limiting safety warnings attached to the final product. The company believes the study results are sufficient to support approval, and intends to file with the FDA in the first half of 2023. If approved for seborrheic dermatitis and atopic dermatitis, that could introduce Arcutis to an additional market value of $27 billion over the next five to seven years, in addition to the $47 billion from plaque psoriasis.

Investors will be looking toward that July 29 PDUFA date for word from the FDA related to plaque psoriasis. In the meantime, investors who are more risk-tolerant could consider buying shares prior to the news. Analysts from Cowenand Mizuho believe peak sales for an approved roflumilast for treatment of psoriasis could hit $1 billion, with Mizuho analyst Uy Ear saying the treatment has blockbuster potential.

Arcutis' stock price has gone from a high of $36 in February 2021, when clinical trials showed promise for roflumilast in treating psoriasis, to a low of $14 this past January due to market volatility and its lack of FDA approval. Now, news of additional trial success and a nearing PDUFA date may be just what the doctor ordered for investors.

The company has funds to support development, along with promising data, and analysts believe the stock price could rise 125%.It could be that the only thing holding the stock back right now is the uncertainty of the broader market, but when you look into the potential for Arcutis, it could be a diamond in the rough for investors.

Continued here:
Could 2023 Be a Breakout Year for This Pharma Stock? - The Motley Fool

Posted in Psoriasis | Comments Off on Could 2023 Be a Breakout Year for This Pharma Stock? – The Motley Fool

Woman covered in psoriasis refuses to hide and can finally look in the mirror – Daily Star

Posted: at 9:37 pm

An influencer who has gone viral thanks to her honesty about her psoriasis has decided to stop receiving treatment.

Claire Spurgin, a junior sommelier from Sussex, spent years covering her red flaky patches of skin out of fear people would make fun of her.

But now aged 25, Claire bravely shares snaps of her body as she refuses to hide from the world any longer.

READ MORE: Woman, 25, covered in psoriasis bravely bares body - 'I refuse to hide any more'

The content creator decided to stop the treatment she was on as it wasnt working.

This means she has to wait a while before she can start another, which resulted in a flare-up.

She regularly updates her followers with the progress of her skin, with one caption reading: I think this is how my skin is now.

My skin flared so much after I stopped treatment but deep down I knew my psoriasis would calm and I just had to get myself through that flare.

Something I didnt talk about was the fact I couldnt go to work for two days because of my psoriasis.

My skin was so sore and I was just too emotional. It's now been two months since I stopped Ciclosporin and my psoriasis may be extremely visible but it doesnt hurt and thats all I ever wanted!

Claire, from Essex, has also opened up about how psoriasis and mental health issues often come hand in hand.

Her honesty has helped educate people about various skin conditions.

When my psoriasis started in 2016 I didnt see light at the end of the tunnel. My skin condition consumed me and its all I could focus on, she explained.

I hated my reflection in the mirror and I lost all confidence. It took years until I was able to say the words I have psoriasis.

My mindset is the complete opposite now and if I can overcome how I felt at 19, then I can do anything!

Its not easy to accept such a change in your appearance but when you realise youre unique, it becomes easier to show your skin.

The influencer said that every skin day is unpredictable and lifestyle choices have a huge effect on her skin.

Unfortunately due to Claires inconsistent working hours in hospitality, it is hard her for to have a consistent routine.

My psoriasis is always changing, some days are oddly calm and other days were flaring out of nowhere, she shared.

For me, there is no telling what my skin will do next and I think thats because every day in life is so different. Lifestyle has a huge effect on our skin.

My routine is always changing and with that so are my emotions. Working hospitality my hours and eating habits have no structure and living in the UK the weather is so diverse.

To stay up to date with all the latest news, make sure you sign up for one of our newsletters here.

Claire said that sometimes you feel like youre in control of your disease and other times you may sink into despair, which is okay.

She added: Its an emotional rollercoaster and its teaching us. We learn and we become stronger but it also humbles us.

The 25-year-olds honesty and openness has helped her grow her Instagram account, which currently has 44,000 followers.

They regularly share their support on her photos.

Still stunning and so brave for sharing your journey with us all, one person wrote.

My beautiful warrior Queen! Stay strong ik [sic] youll find a treatment that will help with your flare-ups, stay positive my love! said another.

A third added: Bless you! Still soooo beautiful!

READ NEXT:

Go here to read the rest:
Woman covered in psoriasis refuses to hide and can finally look in the mirror - Daily Star

Posted in Psoriasis | Comments Off on Woman covered in psoriasis refuses to hide and can finally look in the mirror – Daily Star

Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds – AJMC.com Managed Markets Network

Posted: at 9:36 pm

Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.

While providers are becoming more familiar with the idea of switching patients from reference biologics to biosimilars, it is less common to switch from one biosimilar to another. However, nonmedical switching among biosimilars may occur to save costs.

A study of more than 1500 patients in a real-world setting found switching between infliximab biosimilars was effective and well tolerated. The findings were presented at EULAR 2022, the annual meeting of the European Alliance of Associations for Rheumatology.

The observational cohort study was based on the DANBIO registry and investigated the effectiveness of switching patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) from CT-P13 to GP1111. The study included patients who had been switched from the originator to CT-P13 and patients who had never received the originator product.

Patients were included if they had experienced a biosimilar-to-biosimilar switch between April 1, 2019, and February 1, 2020. The main outcomes were treatment retention on GP1111 after 1 year and changes in disease activity from the 4 months prior to the switch compared with the 4 months after the switch.

The study included 1171 patients who were originator nave and 434 who had already switched from the originator. Among the full population, 685 had RA, 314 had PsA, and 606 had AxSpA. The median disease duration was 9 years. Slightly less than half (42%) were in remission at the time of the switch, according to the Disease Activity Score 28-joint count or Ankylosing Spondylitis Disease Activity Score.

Patients who had been on the originator product had a greater 1-year retention. One year after the switch, 83% (95% CI, 81%-85%) of patients who had never been on the originator maintained GP1111 treatment compared with 92% (95% CI, 90%-95%) of those who had initially switched from the originator. Among patients with RA and PsA, the risk of GP1111 withdrawal was lower among those who had been on the originator; however, there was no significant difference among patients with AxSpA.

For both groups, changes in disease activity were close to zero when comparing the 4 months prior with the 4 months after the switch. Lower disease activity at baseline was associated with higher retention across all 3 disease states. Having 1 or more comorbidities at baseline was also associated with a higher retention of GP1111 at 1 year.

According to the researchers, the difference in retention between the 2 groups suggests retention to be more affected by patient-related than drug-related factors. Overall, the biosimilar-to-biosimilar switch was effective and well tolerated.

According to The Center for Biosimilars, switching among biosimilars was becoming increasingly common in 2019, particularly in countries that utilize tenders for medicines and may ask patients to transition based on the outcomes of tenders.

In 2019, studies presented at United European Gastroenterology Week 2019 and the 6th Congress of Skin Inflammation and Psoriasis International Network had similarly supported the safety and efficacy of multiple biosimilar switching.

References

Nabi H, Hetland ML, Loft AG, et al. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic diseases: clinical outcomes in real-world patients from the DANBIO registry. Presented at: EULAR 2022; June 1-4, 2022; Copenhagen, Denmark. Abstract OP0065.

Read more:
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds - AJMC.com Managed Markets Network

Posted in Psoriasis | Comments Off on Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds – AJMC.com Managed Markets Network

What the DNA of Ancient Humans Reveals About Pandemics – WIRED

Posted: at 9:28 pm

After Hunts unusual flight home, Shanidar Z made it safely to the University of Cambridge for digital scanning and will eventually be transferred back to northern Iraq to feature as the centerpiece of a new museum. The skeleton could be up to 90,000 years old, but its DNA will be used to further understanding of modern human historyby analyzing and statistically comparing the ancient DNA against the genomes of modern populations, to demonstrate when different population groups parted company, Hunt says.

Once a population splits into two or more reproductively isolated groups, the genes in each new population will evolve gradually in new directions as a result of random gene mutations as well as exposure to various environmental factors that prevent successful reproductioncoming into contact with new diseases, for instance.

Its through work like this that scientists have been able to chart the migration of different populations of humans and Neanderthal groups around the planet over the last 70,000 years, and also bust some myths about their habits and migration patterns. We now know that humans and Neanderthals interbred quite commonly, and that Neanderthal communities were likely more caring and intelligent than weve previously given them credit for. According to Hunt, evidence of burial rituals at the Shanidar Cave suggests memory, and that they looked after their injured and sick members.

Separately, analysis of ancient DNA against the modern human genome has revealed that we still carry some genetic sequences that were present in people living millennia ago. Such analysis even helped to identify a new subspecies of humans 12 years agothis discovery of Denisovans, believed to have existed across Asia around 400,000 years ago, demonstrates how much is still unknown about our human origins.

At the Francis Crick Institute in London, a major project is underway to create a reliable biobank of ancient human DNA to help build on such discoveries. Population geneticist Pontus Skoglund is leading the 1.7 million ($2.1 million) project, which will sequence 1,000 ancient British genomes by gathering data from skeletal samples from the past 5,000 years, with help from around 100 other UK institutions. From the database he hopes to determine how human genetics have changed over millennia in response to factors such as infectious diseases and changes in climate, diet, and migration.

Part of that is looking for genetic traits that may have been advantageous for past humans during earlier epidemics, he says. There is no doubt we can learn something from this in our understanding of how we manage contemporary disease and other outbreaks.

Skoglunds team sources their samples from archaeological digs around the country or from museums with existing collections. His favorite bones to sequence are the ones found in our inner ear: These are particularly good at preserving DNA, since they are the least susceptible to microbial invasion and other factors that could cause DNA to deteriorate, he explains.

The bones are ground down to be run through a sequencing machine in much the same way as any DNA sample. But the ancient DNA requires specialist protocolsmodern DNA has very long fragments that are basically intact, whereas with ancient DNA we only get on average around 35 percent of the total base pairs.

Read more:
What the DNA of Ancient Humans Reveals About Pandemics - WIRED

Posted in Human Genetics | Comments Off on What the DNA of Ancient Humans Reveals About Pandemics – WIRED

For the men out there: Do you fall sick often? This might be why – WION

Posted: at 9:27 pm

Do you remember your science lessons from school? Do you remember learning about chromosomes? We were taught that there are two chromosomes X and Y and that each of us has a set of chromosomes. Individuals with XX (or two X chromosomes) are female, while those with XY (or one X and one Y chromosome) are male. A recently published study has now revealed that many men can actually carry an extra chromosome.The study was published in the journal Genetics in Medicine. It included data on more than 207,000 men. It was discovered that of the participants, over 350 had an extra chromosome, either X or Y.Very few of these men knew about this abnormality or had it mentioned in their medical records.

Talking to the Guardian Dr Ken Ong, co-senior author of the study who is a pediatric endocrinologist in the Medical Research Council (MRC) Epidemiology Unit at the University of Cambridge says that they were surprised at how common this abnormality is.

Watch |Robots to solve ocean's pollution menace: 15mm long robo-fish to hunt for plastic

The National Human Genome Research Institute reported that previous estimations indicated that approximately 100 to 200 men out of every 100,000 are XXY. An estimated 18 to 100 out of every 100,000 were believed to be XYY.

Having an extra chromosome can raise the risk of certain health conditions. Those having Klinefelter syndrome (KS) or an extra X chromosome are linked to reproductive problems like infertility and delayed puberty. According to the National Human Genome Research Institute, XXY men are four times more likely than XY men to have late puberty.

Also read |A beer a day might keep your gut flora healthy: Study

On the other hand, with an extra Y chromosome or 47,XYY syndrome does not come with reproductive problems but was linked to learning disabilities, including delay in acquiring speech and motor skills. According to the Genetic and Rare Diseases Information Center, they also have unusually low muscle tone.

Additionally, both XXY and XYY men have a higher rate of type 2 diabetes, atherosclerosis (plaque buildup in the artery walls), pulmonary embolism (blood clots in the veins and lung arteries), and chronic obstructive pulmonary disease (which obstructs airflow to the lungs).

Also read |The tiny mites that have sex on our faces may go extinct

In their report, the authors questioned: "why both KS and 47,XYY should show striking similarities in conferring substantially higher risks for many diseases in common." As per them, future research is needed to examine the reasons causing this elevated risk.

(With inputs from agencies)

Watch WION LIVE HERE:

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

See more here:
For the men out there: Do you fall sick often? This might be why - WION

Posted in Human Genetics | Comments Off on For the men out there: Do you fall sick often? This might be why – WION

The Origins Of Black People With Red Hair – NewsOne

Posted: at 9:27 pm

You might normally associate fiery red hair with people of Irish descent, but the unique trait can also be found throughout a number of diverse ethnic backgrounds.

MORE: The Aboriginal Australians: The First Inhabitants Of Australia Were Black People

Africans and people from the Caribbean have also been known to don bright red hair due to a gene mutation in the melanocortin 1 receptor commonly referred to as MC1R. The special gene regulates melanin in skin pigmentation, the eyes, and hair. However, the distinctive trait only occurs in an individual when both parents carry the unique receptive gene. Scientists believe that the distinct gene mutation is more common in climates where there is little to no harmful sun exposure.

According to the Special Broadcasting Service (SBS), about 35% of people in Ireland and Scotland carry the MC1R receptor and roughly 10% have red hair. Globally, only 1 to 2% of the population have red hair, which is why its quite rare to see Black people with the unique feature, but they do exist.

Barry Starr, a geneticist from Stanford University told Vice that Red hair carriers in the Caribbean and Africa are for the most part due to migration or gene flow.

The last evidence I saw, was that there was a strong selection pressure against changes in the MC1R gene that caused it not to work in regions with a lot of sunlightthink Africa, Dr. Star explained. This probably has to do with the pale skin that comes with red hair. This means that even if an MC1R mutation did spontaneously appear previously in African populations, as it did multiple times in Europe, it did not spread and eventually petered out.

The red hair trait may have developed from historical interactions between Europeans and Africans in the Caribbean in the 1600s. Catholic Irish people were sent to the West Indies as indentured servants during that time period.

This might also explain why you occasionally see red hair on a black Caribbean person who has two black parents. By chance alone, it might be that they are both carrying a European mutation which has come together in their child, Dr. George Busby an expert from the Wellcome Trust Centre for Human Genetics, added to the publication.

Additionally, red hair can also occur in Black people as a result of Albinism, a genetic condition that reduces melanin in the skin. The rare trait usually occurs in people who haverufous Albinism, which, in addition to red hair, can cause an individual to have golden or bronze skin as well as blue eyes.

SEE ALSO:

The History Of Black People With Blue Eyes

Irelands Earliest Inhabitants Were Black People With Blue Eyes

See original here:
The Origins Of Black People With Red Hair - NewsOne

Posted in Human Genetics | Comments Off on The Origins Of Black People With Red Hair – NewsOne

Here’s how Aveva is unlocking the value of industrial data – Gulf Business

Posted: at 9:27 pm

Globally, the Covid-19 pandemic has led to a profound shift in how organisations develop, invest, and deploy technologies to meet their net-zero climate commitments. Companies must consume less energy and use it more efficiently to reduce carbon emissions. Although this sounds easy, we all know its difficult, especially if there is no correct data. Todays digital technologies, data, and artificial intelligence have the power to accelerate businesses sustainability transformation. Aveva has played a central role in helping companies develop energy-related roadmaps and solutions that reduce greenhouse gas emissions while still meeting the worlds energy demands.

The technology sector presents opportunities because we can deploy at scale and connect different companies and different operations through data, which then opens up new insights that can be used to solve sustainability challenges. For example, to address the current climate crisis, we must implement technology that we already have while also innovating to develop new solutions to help reach the internationally agreed goals, said Lisa Wee, vice president Sustainability at Aveva.

Aveva PI WorldAt the recently held Aveva PI World Amsterdam 2022, the company demonstrated how contextualised data is an essential component to sustainable growth in sectors such as power, manufacturing, and infrastructure. Focusing on primarily creating a space for customers and partners to share how they are transforming their organisations and industries, the four-day event, which took place from May 16-19, 2022, gave an overview of the new developments and solutions. Furthermore, the learning labs offered hands-on technical practice in cloud and data environments.

In the keynote speech, Peter Herweck, chief executive officer of Aveva, discussed how the companys information-led innovation provides a proven and flexible path to industrial growth at a critical time when the business landscape has been reshaped by turbulence and risk. Industries are facing complex challenges in a turbulent market environment. Business leaders face increased sustainability compliance requirements, retiring workforces, and the ever-present demand for efficiency, agility and resilience. Raw data in itself is not immediately useful or even understandable, but when you analyse and contextualise it into insightful information, thats when you can help the industrial world to innovate at scale on the road to a net-zero future.

According to the International Energy Agency (IEA), industries have committed to dramatically reducing emissions in the next 25 years. With digitalisation driving sustainability, Aveva aims to help accelerate the organisations to reach their goals. We spark industrial ingenuity by connecting people with trusted information and insights and also help drive responsible use of the worlds resources, he added.

Fostering sustainable use of dataThe event also witnessed Amish Sabharwal, executive vice president of Engineering at Aveva and Gregg Le Blanc, senior vice president of Information Management at Aveva, outline the companys integrated portfolio and elaborate on the product roadmap for 2022 and beyond.Le Blanc pointed out that 50 per cent of data was created in the last two years and how this will continue even in 2024. Meanwhile, according to the Seagate Rethink Data Survey, IDC, 2020, while 56 per cent of data is captured through operations, 68 per cent of data goes unleveraged. With half a century of experience and over 20,000 customers, Aveva believes it is uniquely placed to deliver a complete digital thread purpose built for the industry.

Industrial companies struggle to share timely, accurate data across their global ecosystem. And organisations that share data externally with its partners generate 3X more measurable economic benefit than those that do not, said Le Blanc.We launched Aveva Data Hub earlier this year, a software-as-a-service offering that enables businesses to gain operational efficiencies, boost sustainability and drive digital transformation with data sharing capabilities. Data is the accelerator of the connected economy, and our open and agnostic solutions leverage customers existing investments and enable a connected community across the ecosystem.

Driving digital transformationWith digital twins gaining momentum currently, thanks to rapidly evolving simulation and modelling capabilities, better interoperability and IoT sensors, and more available tools and computing infrastructure, Gartner predicts that the digital twin market will cross the chasm in 2026 to reach $183bn in revenue by 2031. For clarity, a digital twin is a virtual presentation of an object or system that serves as the real-time digital counterpart of a physical object or a process.Digital twin recreates a physical asset in digital form by capturing, organising and contextualising data in a quantifiable form. When these models are used to forecast future scenarios, they can predict potential problems, improve asset reliability, reduce costs and resource use, and minimise carbon emissions, commented Sabharwal.

During the event, Aveva announced that its engineering information management solutions, the core of its digital twin, now deliver more significant time and value gains for capital projects and operations. In addition, its customers can now experience a complete digital twin within just 60 days, even in the absence of existing models. Through two new partnerships, Avevas engineering information management solutions are now integrated with Assais integrated document management system, and data is captured by NavVis wearable mobile mapping systems. As a result, laser scans can be delivered much faster than the existing stationary scanners.Digital twins have never been more important. They will play a central role in uncovering opportunities to unlock ingenuity and achieve the efficiency and sustainability gains needed to enable net-zero carbon emissions, added Sabharwal.

Customer success storiesWith over 2500 delegates joining the event in person and online, more than 70 companies in 12 industry verticals shared their experience of the data-led digital transformation. The guest speaker at the event, Dr Catherine Green, associate professor at the Wellcome Centre for Human Genetics at Oxford University, explains how data helped develop the Oxford vaccine. Despite lockdowns and remote working, we were able to develop and bring to market the Oxford AstraZeneca vaccine in eight months as compared to eight years before the outbreak of Covid-19, thanks to improved data collection, advanced analytics and distributed trials and manufacturing, she commented.

We are at the transition point where you can bring new tech to old problems. And data is going to change everything that we do here. Its going to change our ability to analyse the problem, deliver the solution, and communicate with the healthcare sector and with the public.Michael Dean, global director of Kelloggs Power, Controls and Information System, explained how the companys platform investment has yielded benefits in terms of scale, consistency, standardisation and collaboration. Kelloggs has 50 manufacturing sites worldwide, and installing Aveva PI System has helped leverage, analyse and manage energy data in its factories, creating a digital ecosystem that benchmarked usage and identified opportunities for savings, observed Dean. As a result, we saved $3.3m in a single year, identified an additional $1.8m in rebates, and optimised abatement measures.

Meanwhile, Jan Broekman, vice president of Global Engineering and Smart Modularisation, at McDermott, offered insight into how digital solutions integrated multiple inputs to build a sustainable capital project, including real-time commodity prices and low-carbon design.

The event also witnessed an intriguing panel discussion on digital agility and resiliency. Sophie Borgne, senior vice president Digital Power Line of Business at Schneider Electric, explained how they have cut carbon emissions by 25 per cent. We have been looking at sustainability for a long time, and earlier, we lacked real-time data and insight on how to improve operational efficiency. Our partnership with Aveva helped deploy the right tools, which increased the visibility and real-time information to help operators make the right decisions. As a result, we reduced electricity use by 25 per cent, and also we cut overall carbon emission by 25 per cent. Meanwhile, Dean stated the explicit goals of Kelloggs for 2030 and 2050. We look at how to manufacture products more sustainably. For instance, we leveraged the Aveva PI System, which significantly reduced our energy consumption.

Jacky Wright, the chief digital officer at Microsoft, talked about how data accelerates sustainability progress. A cloud-based, data-driven approach enabled us to assess, select and build new technologies, and reduce our scope 1, scope 2, and, ultimately, scope 3 emissions across our business. She further explained how data analytics has supported smart buildings, investment in renewable energy to power data centres, and driven strategic decisions to pay for the removal of 1.3 million metric tonnes of carbon dioxide from the atmosphere.

Whats nextAveva envisions optimising the entire industrial ecosystem, connecting people with industrial intelligent-as-a-service. We apply the advanced, proven technologies to drive our customers success and enable them to achieve more. Going forward, we are building blocks for the Aveva industrial metaverse using Aveva XR to solve many different customers use cases in operations engineering, said Andrew McCloskey, CTO and EVP R&D in the closing note.

The rest is here:
Here's how Aveva is unlocking the value of industrial data - Gulf Business

Posted in Human Genetics | Comments Off on Here’s how Aveva is unlocking the value of industrial data – Gulf Business

Unleash the Superpowers of Your One and Only Employees – MIT Sloan

Posted: June 22, 2022 at 12:31 pm

Topics Column

Our expert columnists offer opinion and analysis on important issues facing modern businesses and managers.

Jackie Robinson syndrome is the condition where, as a member of an underrepresented group, you are the first in something, the One and Only, and there is a perception that you must be both exceptional and perform at a higher standard than others. (This syndrome is named for the American superstar athlete who, in 1947, became the first Black player invited into Major League Baseball.) Many who operate with this status are often seen as anomalies.

Although embracing these anomalous qualities can cause isolation, especially at the beginning, as anomalies continue to survive, over time they set new baselines for normal. One and Onlys are often seen as trailblazers because they show us what is possible. They instinctively understand this human peculiarity: They work hard to embrace their differences, to stand out and not blend in. When a One and Only lives their life always being different, it means they inherently have learned to think outside the box.

Providing support for unique employees doesnt come naturally in most organizations. There can be bias against embracing the exceptions, even when they are exceptional. But One and Onlys have the power to lead change, which organizations should embrace and provide scaffolds to amplify.

Get Updates on Transformative Leadership

Evidence-based resources that can help you lead your team more effectively, delivered to your inbox monthly.

Please enter a valid email address

Thank you for signing up

Privacy Policy

In the engineering world, we are typically encouraged to get rid of anomalies. Since they can negatively impact our data analysis or how we design a normative solution, anomalies are often discarded.

This bias against outliers and difficult-to-measure data can get baked into processes in extremely detrimental ways. In 1977, for instance, a U.S. Food and Drug Administration policy recommended excluding women of childbearing age from early drug trials following the discovery that a drug used to prevent morning sickness could cause severe birth defects, such as missing limbs. Many absurdities ensued, including a trial that studied whether hormone therapy was an effective treatment for mitigating heart disease after menopause that had 8,341 men enrolled and zero women. It wasnt until 1993 that the FDA explicitly reversed the recommendations from its 1977 policy. The damage they caused has yet to be fully resolved, because most of the advances the medical sciences have made are still rooted in original studies involving the male body. A 2020 study based on data from over 2 million patients revealed that women with heart disease are less likely than men to receive the recommended medication.

A similar bias to test with the male as the norm has plagued the auto industry. Since the 1970s, most crash tests designed to assess car safety designs have used crash test dummies that are standardized to the average American male body. The National Highway Traffic Safety Administration, an agency of the U.S. federal government that has oversight of automobile safety, didnt begin to make wider use of female dummies in crash tests until 2003. The consequences are sobering: A 2019 University of Virginia study provided evidence that a female car occupant has a 73% greater chance of being seriously injured in a frontal car crash compared with a male occupant.

These are two real-world examples of what can happen when the experiences and voices of those outside the defined normal become muted during the innovation process.

Sometimes scientists choose to deal with anomalies not by discarding them from the data set but by analyzing them to figure out why they exist. How is it that a few metastatic breast cancer patients survive when most do not? How is it that, when an entire community contracts COVID-19, one or two people fly through with no symptoms? How is it that most people die before the age of 100, but a select few live to be centenarians? These are questions that are obviously worth embracing.

We dont need to look far to find proof that when anomalies are not discarded but treated as royalty, they can change the world. Just think about the story of Henrietta Lacks, an African American woman who was diagnosed with terminal cervical cancer in 1951. After her cancer cells were collected and cultivated, they were found to be unusually resilient in the lab, and they were used to unlock some of the biggest advances in medical science. They were the first immortal cells to live outside the human body, and for the past 60 years, Lackss cells, called HeLa cells, have been essential to marvelous medical advances ranging from the polio vaccine to chemotherapy and gene mapping. Of course, her cells were taken without her explicit permission , which is counter to the practices that organizations should follow when they encounter anomalies.

Anomalies have the ability to make a big difference, both in laboratories, like with Lackss cells, and in the professional world, the way Jackie Robinson did.

For organizations, anomalies can be seen as that talent that lies within their own ranks people who stand out from their peers and whom many might consider an unexpected success.

To maximize their competitiveness, businesses should not only lean into cultivating One and Onlys but also create a supportive environment where they can thrive even before they are identifiable as that rare anomalous gem.

Here are three ways businesses can utilize differences to lead in change:

Put anomalies in positions of leadership. The fact that One and Onlys are present in worlds where they stand alone in the first place means theyve navigated tougher challenges than most. One study, for instance, found that while the number of women-owned businesses grew nationally by 21% from 2014 to 2019, the numbers for African American/Black women grew even faster, by 50%. When One and Onlys are put in positions of leadership, they must be actively supported by management especially as many are less likely to receive help from organizational structures, be openly provided the resources they need to succeed, or have their accomplishments promoted.

Support bravery. It can take a huge amount of courage for One and Onlys to speak up, especially if their opinions are different from whats being voiced by everyone around them. Leaders have an important role in creating an environment that encourages divergent viewpoints. Leaders must explicitly ask for everyones opinion during team meetings to encourage that anomalous discovery. Dont shut down any ideas, even if they make you uncomfortable. Just like when working with neurodiverse talent, giving feedback that is tailored in response to the individuals diverse viewpoint can help create a more inclusive work environment.

Go back to the well. Companies should revisit the sourcing pipelines that got them to a broader range of job candidates. There are other One and Onlys who may be in the same place where the first one was found. Once Jackie Robinson broke through into the mainstream major leagues, the baseball world realized there was an entire group of players in the Negro Leagues who could be tapped. It changed the normative for the entire sport.

Our expert columnists offer opinion and analysis on important issues facing modern businesses and managers.

Ayanna Howard (@robotsmarts) is dean of the College of Engineering at The Ohio State University.

Link:
Unleash the Superpowers of Your One and Only Employees - MIT Sloan

Posted in Immortality Medicine | Comments Off on Unleash the Superpowers of Your One and Only Employees – MIT Sloan

Inside the Push to Diversify the Book Business – The New York Times

Posted: at 12:31 pm

Some editors, like Lucas, are trying to figure out how to do the same for the vast swaths of America that big publishers have mostly ignored. Its an effort that is complicated by a long history of neglect, which itself is bound up with publishers failure to take diversity in their own professional ranks seriously until recently. In interviews with more than 50 current and former book professionals and authors, I heard about the previous unsuccessful attempts to cultivate Black audiences and about an industry culture that still struggles to overcome the clubby, white elitism it was born in. As Lucas sees it, the future of book publishing will be determined not only by its recent hires but also by how it answers this question: Instead of fighting over slices of a shrinking pie, can publishers work to make the readership bigger for everyone?

When I entered the world of book publishing where I spent two years as an assistant and another 16 as a book-review editor, critic and reporter Barbara Epler, now the publisher of New Directions, warned me that the entry-level pay was abysmal, in large part because publishers assumed that few of their entry-level hires would actually have to survive on it: Historically, salaries were considered dress money. She said it with an outraged laugh, and I thought it was a joke, but I soon learned that she was right. When I was hired at Farrar, Straus & Giroux in 1997, I made $25,000 a year for a job that required a college degree, industry experience and often more than 60 hours a week. I could have earned more money temping. Over the years, publishers remained reluctant to raise wages. In 2018, according to a Publishers Weekly industry survey, the median salary for an editorial assistant was $38,000.

For much of its history, book publishing, especially literary book publishing, was an industry built and run by rich, white men. One of the founders of Farrar, Straus & Giroux was Roger Straus Jr., whose mother was an heir to the Guggenheim fortune and whose fathers family ran Macys department store. Grove Press was owned by Barney Rosset, whose father owned banks in Chicago. When Bennett Cerf, the son of a tobacco-distribution heiress, bought the Modern Library, which would be renamed Random House in 1927, he and his partner, Donald Klopfer, each ponied up $100,000 roughly the equivalent of $1.7 million today.

Until the 1960s, American literature was shaped by the fact that Black authors needed white publishers to achieve national recognition. In her recent article for Publishers Weekly, Black Publishing in High Cotton, Tracy Sherrod, an executive editor at Little, Brown who was the editorial director of the Black-themed imprint Amistad Press for nine years notes that both the poet Langston Hughes and the novelist Nella Larsen got book deals in the 1920s with the help of Blanche Knopf, an editor at the prestigious publishing house Alfred A. Knopf. After that, you could always point to a few great Black authors published by New York houses. Yet white editors didnt necessarily think of themselves as serving Black readers.

There is a subgenre of essay in the African American literary tradition, that can loosely be called What White Publishers Wont Print, Henry Louis Gates Jr., a professor of English at Harvard, said. Both James Weldon Johnson and Zora Neale Hurston wrote essays with that title, more or less. Gates said, There is a consciousness from almost 100 years ago among Black writers about the racial limitations and biases of the American publishing industry. Richard Wright, whose 1940 novel Native Son sold 215,000 copies in three weeks, for example, still saw half of his 1945 memoir Black Boy expurgated to please the Book-of-the-Month Club, which catered to an audience of white middle-class readers.

Under pressure from the civil rights movement, Americas big publishing houses embarked on their first effort to serve a more diverse market in the 1960s. Teachers and school boards in cities like Chicago and New York were demanding schoolbooks that recognized the histories and experiences of nonwhite Americans. On Capitol Hill, Representative Adam Clayton Powell Jr., Democrat of New York, investigated the portrayal of minorities in classroom writings as part of the Ad Hoc Subcommittee on De Facto Segregation in 1966. His hearings revealed that there was only a single Black editor leading any of the new schoolbook series that publishers had established: Doubleday and Companys Charles F. Harris. In response to this revelation, many publishers began recruiting Black editors into their education divisions, and a few of these editors later moved to the companies general trade-book divisions as well. Those were the glory days, Marie Brown, who was hired by Doubleday in 1967, told me. We were invited in. Among the ranks of these new hires was the future Nobel Prize winner Toni Morrison, who worked in a scholastic division of Random House while writing her first novel, The Bluest Eye.

Link:
Inside the Push to Diversify the Book Business - The New York Times

Posted in Immortality Medicine | Comments Off on Inside the Push to Diversify the Book Business – The New York Times

Page 280«..1020..279280281282..290300..»